The presentation and correlation research of VEGF, Ang-2 and SUVmax of PET/CT in solitary pulmonary nodule
-
摘要:
目的探讨VEGF、Ang-2与PET/CT SUVmax值在孤立性肺肿块的表现及相关性,旨在为孤立性肺肿块性质判定及治疗提供依据。 方法选取2014年1月~6月连续性孤立性肺肿块患者89例,根据病理分成良性组、恶性组,术前用PET/CT测定病灶SUVmax值,术后用免疫组织化学方法检测病灶VEGF、Ang-2表达,比较良、恶性组间VEGF、Ang-2、SUVmax值,绘制ROC曲线找出三者诊断肺肿块良恶性的最佳截点,并对VEGF、Ang-2与SUVmax值做相关性分析。 结果(1)恶性组中的VEGF、Ang-2、SUVmax值均大于良性组,差异有统计学意义(P < 0.05);(2)ROC曲线分析结果显示VEGF=89.0,Ang-2=81.5,SUVmax值=2.85时,诊断孤立性肺肿块恶性的敏感性分别为75%、82.8%、92.2%,特异性分别为80.0%、76.0%、64.0%;(3)良性组中VEGF(r=0.534,P=0.006)、Ang-2(r=0.558,P=0.004)与SUVmax值具有相关性;恶性组中VEGF(r=0.575,P=0.000)、Ang-2(r=0.598,P=0.000)与SUVmax值具有相关性。 结论VEGF、Ang-2与SUVmax值在肺恶性肿瘤表达高于良性,且存在相关,对肺肿瘤良恶性质判断及治疗有指导作用。 -
关键词:
- 孤立性肺肿块 /
- 血管内皮生长因子 /
- 血管生成素-2 /
- 正电子发射断层显像术
Abstract:Objective To analyze the correlation of VEGF, Ang-2 and SUVmax of PET/CT in benign and malignant lung tumor, provide the basis of the property determination of lung tumor. Methods Eighty-nine solitary pulmonary nodules patients of our hospital from Jan. 2014 to June 2014 were selected as research objectives. All patients were divided by pathological grading after operative treatment. All patients were tested by PET/CT before operative treatment and the diameter of lesions, SUVmax were tested. The tumor tissue were acquired after surgery and the expression of VEGF and Ang-2 were tested by immunohistochemical. Taken together, ROC curve was evaluated by measured value and the best cutoff point for pulmonary lumps diagnosis was demonstrated by VEGF, Ang-2 and SUVmax. Results (1) The VEGF, Ang-2 and SUVmax of malignant lung tumor patients were higher than benign lung tumor patients with significant differences (P < 0.05). (2) ROC curve analysis showed that VEGF=89.0, Ang-2=81.5, SUVmax value=2.85, the sensitivity of the diagnosis of isolated pulmonary lumps malignant were 75%, 82.8%, 92.2%, specificity of 80.0%, 76.0%, 64.0% respectively. (3) VEGF in benign group (r=0.534, P=0.006), Ang-2(r=0.558, P=0.558) were correlated with SUVmax. In malignant lung tumor patients, VEGF (r=0.575, P=0.000) and Ang-2 (r=0.598, P=0.000), were correlated with SUVmax. Conclusion The expression of VEGF, Ang-2 and the value of SUVmax in PET/CT tests in malignant lung tumor patients were higher than that in benign lung tumor patients, which can provide the basis of the property determination of lung tumor. -
表 1 良、恶性占位组间各参数比较
组别 n 大小(cm) VEGF Ang-2 SUV 良性 25 2.3(2.7) 72.0(29.0) 74.0(29.0) 2.6(4.7) 恶性 64 2.8(2.2) 110.5(50.0) 109.0(52.0) 9.9(8.1) Z -1.594 -4.827 -4.481 -4.816 P 0.111 0 0 0 -
[1] Jain RK, Munn LL, Fukumura D. Dissecting tumourpathophysiology using intravital microscopy[J]. Nat Rev Cancer,2002, 2(4): 266-76. doi: 10.1038/nrc778 [2] Hanahan D, Weinberg RA. Hallmarks of Cancer: the nextGeneration[J]. Cell, 2011, 144(5): 646-74. doi: 10.1016/j.cell.2011.02.013 [3] Carmeliet P. Angiogenesis in Life, disease and medicine[J]. Nature,2005, 438(770): 932-6. [4] 王蓓, 宋璐. 孤立性肺结节的诊断与鉴别诊断[J]. 临床内科杂志,2010, 27(8): 509-11. [5] Cho JS, Kang JH, Han IH, et al. Activation of TLR4 induces VEGFexpression via Akt pathway in nasal polyps[J]. Clin Exp Allergy,2013, 43(9): 1038-47. doi: 10.1111/cea.2013.43.issue-9 [6] Kaira K, Oriuchi N, Shimizu K, et al. Evaluation of thoracic tumorswith (18)F-FMT and (18)F-FDG PET-CT: a clinicopathologicalstudy[J]. Int J Cancer, 2009, 124(5): 1152-60. doi: 10.1002/ijc.v124:5 [7] 丁重阳, 黄庆娟, 李天女, 等. 18F-FDG PET/CT显像诊断肺癌的价值[J]. 南京医科大学学报:自然科学版, 2010(2): 191-4. [8] Carney DN. Lung cancer--time to move on from chemotherapy[J].N Engl J Med, 2002, 346(2): 126-8. doi: 10.1056/NEJM200201103460211 [9] Janne PA, Engelman JA, Johnson BE. Epidermal growth factorreceptor mutations in non-small-cell lung Cancer: Implications fortreatment and tumor biology[J]. J Clin Oncol, 2005, 23(14):3227-34. doi: 10.1200/JCO.2005.09.985 [10] Kaira K, Oriuchi N, Shimizu K, et al. Correlation of angiogenesiswith 18F-FMT and 18F-FDG uptake in non-small cell lung Cancer[J]. Cancer Sci, 2009, 100(4): 753-8. doi: 10.1111/cas.2009.100.issue-4 [11] Liu X, Zhang H, Yu X, et al. The correlation of expression ofVEGF and EGFR with SUV of (18)FDG-PET-CT in non-small celllung Cancer[J]. Contemp Oncol (Pozn), 2014, 18(5): 334-9.